Reply to Ciccolini et al.: Using mathematical modeling to predict response to antiangiogenic therapy in cancer patients
dc.contributor.author | Duda, D. G. | en |
dc.contributor.author | Heist, R. S. | en |
dc.contributor.author | Sahani, D. V. | en |
dc.contributor.author | Stylianopoulos, T. | en |
dc.contributor.author | Engelman, J. A. | en |
dc.contributor.author | Jain, R. K. | en |
dc.creator | Duda, D. G. | en |
dc.creator | Heist, R. S. | en |
dc.creator | Sahani, D. V. | en |
dc.creator | Stylianopoulos, T. | en |
dc.creator | Engelman, J. A. | en |
dc.creator | Jain, R. K. | en |
dc.date.accessioned | 2019-05-06T12:23:32Z | |
dc.date.available | 2019-05-06T12:23:32Z | |
dc.date.issued | 2015 | |
dc.identifier.uri | http://gnosis.library.ucy.ac.cy/handle/7/48319 | |
dc.language.iso | eng | en |
dc.source | Proceedings of the National Academy of Sciences of the United States of America | en |
dc.subject | mathematical model | en |
dc.subject | antineoplastic agent | en |
dc.subject | cancer chemotherapy | en |
dc.subject | human | en |
dc.subject | Humans | en |
dc.subject | cancer patient | en |
dc.subject | female | en |
dc.subject | cancer combination chemotherapy | en |
dc.subject | cancer survival | en |
dc.subject | carboplatin | en |
dc.subject | paclitaxel | en |
dc.subject | priority journal | en |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | en |
dc.subject | drug efficacy | en |
dc.subject | Lung Neoplasms | en |
dc.subject | Carcinoma | en |
dc.subject | male | en |
dc.subject | Antibodies | en |
dc.subject | monoclonal antibody | en |
dc.subject | treatment response | en |
dc.subject | Non-Small-Cell Lung | en |
dc.subject | Monoclonal | en |
dc.subject | Letter | en |
dc.subject | Humanized | en |
dc.subject | Neovascularization | en |
dc.subject | Pathologic | en |
dc.subject | Vascular Endothelial Growth Factor A | en |
dc.subject | vasculotropin A | en |
dc.subject | antiangiogenic therapy | en |
dc.subject | angiogenesis inhibitor | en |
dc.subject | Angiogenesis Inhibitors | en |
dc.subject | antagonists and inhibitors | en |
dc.subject | mathematical parameters | en |
dc.subject | non small cell lung cancer | en |
dc.subject | tumor blood flow | en |
dc.title | Reply to Ciccolini et al.: Using mathematical modeling to predict response to antiangiogenic therapy in cancer patients | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1073/pnas.1507225112 | |
dc.description.volume | 112 | |
dc.author.faculty | Πολυτεχνική Σχολή / Faculty of Engineering | |
dc.author.department | Τμήμα Μηχανικών Μηχανολογίας και Κατασκευαστικής / Department of Mechanical and Manufacturing Engineering | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Stylianopoulos, T. [0000-0002-3093-1696] | |
dc.description.totalnumpages | E3454 | |
dc.gnosis.orcid | 0000-0002-3093-1696 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |